Status and phase
Conditions
Treatments
About
The incidence of obesity has dramatically increased during the last three decades, leading to a significant increase of obesity-related morbidity, including type 2 diabetes mellitus (T2DM) that is characterized by resistance of target tissues to insulin action. T2DM obese patients may be treated by medications or by bariatric surgery. Both alternatives have limitations due to incomplete resolution of the diseases, high cost or potential procedural related morbidity. An increasing body of evidence points to a role of the enteric microbiota in the pathogenesis of obesity-related insulin resistance. In addition to that, the gut microbiota is directly affected by the diet composition. Studies in T2DM mice carrying human gut germs, demonstrated special interactions between the gut microbiota and the host, creating a typical microbiota composition which changes significantly following diet change from a western diet, rich with sugar, to a vegetarian diet rich with fibers. This rapid alternations in the microbiota composition has also shown in humans, after changing from western to high fiber diet. A change in diet life style may lead to an improvement in T2DM symptoms such as decrease in visceral adipose tissue.
Full description
Study design:
30 Patients will undergo 2 FMT's from a lean donor and will be randomized into 3 types of diet groups:
The treating physicians and the patients will be blinded for the diet arm. Before and after FMT, patients will be assessed after an overnight fast (and before taking medications) for weight, anthropometric measures, questionnaires (dietary, general health, antibiotic and probiotic exposure, oral diabetes medication quantity, and other drug exposure), blood and stool.
The investigators hypothesize that fecal microbial transplantation from a lean donor to T2DM obese patients, with the combination of low fat high fiber diet, will alter the gut microbiota composition to decrease insulin resistance through microbiota dependent metabolic and immunologic effects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
30≤BMI
A diagnosis of T2DM (≥3 months) and one of the following:
Access to a smart phone supporting the research application for tracking food consumption.
Exclusion criteria
Patients will also be excluded if:
Primary purpose
Allocation
Interventional model
Masking
30 participants in 3 patient groups
Loading...
Central trial contact
Nitsan Maharshak, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal